Pfizer: preliminary results of a study on UCART19.

(CercleFinance.com) - Servier, Pfizer and Cellectis today announced that preliminary results from two phase 1 trials with UCART19 will be presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in Atlanta on 9-12 December.


The CALM study is an open label, dose-escalation study designed to evaluate safety, tolerability and anti-leukemic activity of UCART19 in patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

PALL is an open, non-comparative phase 1 study designed to evaluate the safety and capacity of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.


Copyright (c) 2017 CercleFinance.com. All rights reserved.